The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending nivolumab-relatlimab (Opdualag) for people aged 12 or older with untreated advanced melanoma, making nearly 1300 patients eligible for the treatment.1
The combination of two monoclonal antibodies is given …